Pembrolizumab news

All news on Pembrolizumab (also known as KEYTRUDA): plants, production capacities, investments and involved companies.

30 October 2025
Merck Announces Q3 2025 Financial Results
Sales rose 4% to $17.3B. KEYTRUDA up 10%, GARDASIL down 24%. GAAP EPS $2.32, Non-GAAP $2.58. FDA approved KEYTRUDA QLEX. Acquired Verona Pharma. Full-year sales outlook: $64.5B-$65B.
29 October 2025
Merck and Eisai Update on LEAP-012 Trial for Hepatocellular Carcinoma
The LEAP-012 trial showed no overall survival benefit for the treatment, but progression-free survival improved. The study is closed, and further data analysis is ongoing.
29 October 2025
Merck's KEYTRUDA Approved in EU for Treating Resectable LA-HNSCC
KEYTRUDA gains EU approval as the first anti-PD-1 therapy for resectable LA-HNSCC with PD-L1 expression, based on KEYNOTE-689 results.
28 October 2025
Merck's KEYTRUDA and WELIREG Combo Improves DFS in RCC Patients Post-Nephrectomy
The LITESPARK-022 trial shows improved DFS with KEYTRUDA and WELIREG in RCC patients. Safety profiles align with previous studies. Results to be shared with regulators.
28 October 2025
Merck and Eisai's WELIREG and LENVIMA Improve PFS in Advanced Renal Cell Carcinoma Trial
The trial showed significant PFS and ORR improvements with WELIREG and LENVIMA in advanced RCC patients post anti-PD-1/L1 therapy, with consistent safety profiles.
23 October 2025
Merck's KEYTRUDA and KEYTRUDA QLEX Get FDA Priority Review for Bladder Cancer Treatment
FDA grants priority review for KEYTRUDA combinations with Padcev, showing improved survival in muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy.

Who will be producing Pembrolizumab in the future?

Find out with chemXplore Analytics